Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy

On March 18, Medicilon Inc. (Medicilon) and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.

Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy.webp

Two-way development, move forward together
Improve the efficiency of RNA, cell and genetic drug research and development

In the exploration of the field of biopharmaceutical, RNA, cell and gene therapy are gradually becoming emerging forces leading the development of the industry with their unique advantages and potential. These cutting-edge therapies not only open up new path for disease treatment, but also provide new opportunities for biopharmaceutical companies.

As a CRO deeply involved in the field of biopharmaceutical preclinical R&D, Medicilon keeps up with the trends and involved in cutting-edge fields such as bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT. Medicilon has helped 421 INDs pass the approval of China's NMPA, the US FDA, the EU's EMA and the Australian TGA to enter clinical trials.

Innoforce is a global biopharmaceutical contract development and manufacturing organizations (CDMO) serving domestic and foreign clients. Focusing on areas such as RNA and cell therapy products, Innoforce is committed to providing one-stop CDMO solutions including plasmids, viral vectors, cell therapy products, RNA and LNP to advanced therapy drug partners.

Dedicated to empowering the cutting-edge areas of drug research and development, Medicilon and Innoforce have reached a strategic collaboration based on the same vision and complementary technical advantages. According to the strategic collaboration agreement, the two parties will conduct all-round strategic collaboration in business collaboration, resource sharing, global promotion, joint development and commercial licensing. This collaboration not only achieves the complementary advantages and efficient integration of the resources of both parties, but also demonstrates profound insights and firm confidence in the fields of advanced therapies such as RNA, cell and gene therapy, and will also lead the entire biopharmaceutical industry towards higher and further goals.

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客